Cybin Inc (CYBN) Reports Publication of Research Manuscript in the Journal of Medicinal Chemistry
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/11/2026
- Wall St climbs after August inflation report, oil price slide
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but on track for 8% weekly gain on supply concerns; US diesel hits record high
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Cybin Announces Publication of Research Manuscript in the Journal of Medicinal Chemistry
April 18, 2024 7:30 AM EDT- Publication explores structure-activity relationships (SAR) of a broad range of 2C-X analogs -
- Innovative research led to the discovery of CYB210010, a potent and long-acting serotonin 5-HT2 receptor agonist with favorable pharmacokinetic properties -
TORONTO--(BUSINESS WIRE)-- Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) (Cybin or the Company), a clinical-stage biopharmaceutical company committed... More
